Description_x000D_ General description_x000D_ Anti-Splicing Factor SC-35 antibody, Mouse monoclonal (mouse IgG1 isotype) is derived from the SC-35 hybridoma produced by the fusion of mouse myeloma cells and splenocytes from a RBF-DHJ mouse immunized with partially purified spliceosomes prepared from HeLa cells. Splicing Factor SC-35, also known as serine/arginine rich splicing factor 2 (SRSF2) belongs to the family of of serine/arginine-rich (SR) proteins._x000D_ Immunogen_x000D_ partially purified spliceosomes prepared from HeLa cells_x000D_ Application_x000D_ Anti-Splicing Factor SC-35 antibody has been used in_x000D_ • dot blot_x000D_ • enzyme linked immunosorbent assay (ELISA)_x000D_ • immunofluorescence_x000D_ • immunohistochemistry_x000D_ • immunoblotting_x000D_ • immunoprecipitation_x000D_ Physical form_x000D_ Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide._x000D_ Disclaimer_x000D_ Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals._x000D_ Biochem/physiol Actions_x000D_ Splicing Factor SC-35 are critical regulators of constitutive and alternative pre-mRNA splicing. It also controls cellular apoptosis in response to genotoxic stress. Serine/arginine protein kinase 1 (SRPK1) specifically phosphorylates SC-35, resulting in p53 suppression and cyclin D1 upregulation. Elevated levels of SC-35 correlate with aggressive phenotype in several cancer types including lung squamous cell carcinoma and lung adenocarcinoma. SC-35 has oncogenic function in tumor progression of human papilloma virus (HPV)-infected cells.